Bank of New York Mellon Corp Acquires 194,559 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Bank of New York Mellon Corp grew its holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 474.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 235,593 shares of the company’s stock after purchasing an additional 194,559 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.15% of Neumora Therapeutics worth $2,316,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Amalgamated Bank bought a new stake in Neumora Therapeutics during the 4th quarter valued at $29,000. SG Americas Securities LLC bought a new position in Neumora Therapeutics in the second quarter worth about $566,000. Nan Fung Group Holdings Ltd bought a new stake in shares of Neumora Therapeutics in the 1st quarter valued at about $871,000. Auour Investments LLC purchased a new position in shares of Neumora Therapeutics in the 1st quarter worth approximately $1,445,000. Finally, Kennedy Capital Management LLC bought a new position in shares of Neumora Therapeutics during the 1st quarter worth approximately $1,881,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $29.00 price target on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. Mizuho initiated coverage on Neumora Therapeutics in a report on Monday, July 8th. They issued an “outperform” rating and a $20.00 price target for the company. Finally, Needham & Company LLC restated a “buy” rating and set a $23.00 price objective on shares of Neumora Therapeutics in a report on Thursday, September 12th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.11.

Neumora Therapeutics Price Performance

Shares of NMRA stock opened at $11.94 on Tuesday. Neumora Therapeutics, Inc. has a 52-week low of $8.33 and a 52-week high of $21.00. The business has a 50-day simple moving average of $11.62 and a 200-day simple moving average of $11.51.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.37) EPS for the quarter, hitting the consensus estimate of ($0.37). As a group, sell-side analysts expect that Neumora Therapeutics, Inc. will post -1.51 EPS for the current year.

Insider Activity at Neumora Therapeutics

In other Neumora Therapeutics news, CFO Joshua Pinto sold 31,642 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $11.78, for a total value of $372,742.76. Following the completion of the transaction, the chief financial officer now owns 154,658 shares in the company, valued at $1,821,871.24. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 26.40% of the stock is owned by company insiders.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.